Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
February 08, 2024 05:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of...
Advanced Therapy Medicinal Products Market to Accumulate a Valuation of USD 61.5 Billion by 2030, Advancing at a 13.4% CAGR | MarketDigits
February 06, 2024 07:15 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 06, 2024 (GLOBE NEWSWIRE) -- According to a research report "Advanced Therapy Medicinal Products Market”, by Therapy Type (Cell Therapy {Stem Cell Therapy, Non-stem Cell Therapy},...
Global DLL3 Targeted Therapy Market Research Report 2024 - Innovations, Opportunities, Market Trends & Clinical Trials Insights
February 01, 2024 03:16 ET
|
Research and Markets
Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
Asia-Pacific Cell and Gene Therapy Biomanufacturing Analysis and Forecast, 2022-2031 - A $8.60 Billion Projected Market by 2031
January 30, 2024 13:04 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Cell and Gene Therapy Biomanufacturing Market - Analysis and Forecast, 2022-2031" report has been added to ResearchAndMarkets.com's...
NMDP BioTherapies Appoints New President to Lead Next Phase in Life-Saving Therapy Development
January 30, 2024 09:00 ET
|
NMDP
NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president.
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
January 29, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
January 29, 2024 07:00 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Autologous Cell Therapy Global Research Report 2024: Market to Surge to $19.53 Billion by 2028, Propelled by Technological Advances and Aging Population Growth - Forecast to 2033
January 25, 2024 09:22 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Autologous Cell Therapy Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global autologous cell therapy...
Global Cell Therapy Raw Materials Market Report 2024-2034: Three-Dimensional Techniques, Aseptic Innovations, and Advanced Cell Therapy Raw Materials Driving the Industry
January 24, 2024 14:34 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Cell Therapy Raw Materials Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The...
Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical Recognition, and Fast Track Designation Regulatory Approvals
January 24, 2024 14:23 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. With the...